Exendin-3 (9-39) is a potent and selecive GLP-1 receptor antagonist.
CAT No: R1827
CAS No:133514-43-9
Synonyms/Alias:133514-43-9;Exendin (9-39);Avexitide;exendin(9-39);Asp-LEU-SER-LYS-GLN-MET-GLU-GLU-GLU-ALA-VAL-ARG-LEU-PHE-ILE-GLU-TR|p|-LEU-LYS-ASN-GLY-GLY-PRO-SER-SER-GLY-ALA-PRO-PRO-PRO-SER-NH2;ASP-LEU-SER-LYS-GLN-MET-GLU-GLU-GLU-ALA-VAL-ARG-LEU-PHE-ILE-GLU-TRP-LEU-LYS-ASN-GLY-GLY-PRO-SER-SER-;DTXSID00158156;Exendin (9-39) Acetate;exendin-(9-39) amide;Exendin-3 9-39)amide;Exendin-3 (9-39);Exendin-3-(9-39) amide;GTPL1138;CHEMBL4070972;GTPL13444;GLXC-27747;EX-A7432;AKOS024456934;AS-83777;CID 16198321;DA-73276;FE110341;exendin 3 [Heloderma horridum horridum (Mexican beaded lizard)] (9-39)-peptide 39-amide (from INN record);
2. The spatiotemporal control of signalling and trafficking of the GLP-1R
3. High fat diet and GLP-1 drugs induce pancreatic injury in mice
4. Store-operated Ca2+ entry sustains the fertilization Ca2+ signal in pig eggs
5. Cationic cell-penetrating peptides are potent furin inhibitors
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.